2,6-diisopropylphenyl {[1-(2-methoxyphenyl)-4-(3-methoxyphenyl)piperidin-4-yl]carbonyl}sulfamate | 867262-98-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2,6-diisopropylphenyl {[1-(2-methoxyphenyl)-4-(3-methoxyphenyl)piperidin-4-yl]carbonyl}sulfamate
• 英文别名: 2,6-Diisopropylphenyl{[1-(2-Methoxyphenyl)-4-(3-methoxyphenyl)piperidin-4-yl]carbonyl}sulfamate；[2,6-di(propan-2-yl)phenyl] N-[1-(2-methoxyphenyl)-4-(3-methoxyphenyl)piperidine-4-carbonyl]sulfamate
• CAS: 867262-98-4
• 化学式: C₃₂H₄₀N₂O₆S
• 分子量: 580.745
• InChiKey: YTGXRDAGKLLTFJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.9
• 重原子数：
  41
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  103
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2,6-diisopropylphenyl {[1-(2-methoxyphenyl)-4-(3-methoxyphenyl)piperidin-4-yl]carbonyl}sulfamate 在 sodium t-butanolate 作用下， 以 甲醇 为溶剂， 反应 0.5h， 以96%的产率得到2,6-diisopropylphenyl {[1-(2-methoxyphenyl)-4-(3-methoxyphenyl)piperidin-4-yl]carbonyl}sulfamate sodium salt
  参考文献：
  名称：

  A Novel Class of Antihyperlipidemic Agents with Low Density Lipoprotein Receptor Up-Regulation via the Adaptor Protein Autosomal Recessive Hypercholesterolemia

  摘要：

  We have previously reported compound 2 as a inhibitor of acyl-coenzyme A:cholesterol O-acyltransferase (ACAT) and up-regulator of the low density lipoprotein receptor (LDL-R) expression. In this study we focused on compound 2, a unique LDL-R up-regulator, and describe the discovery of a novel class of up-regulators of LDL-R. Replacement the methylene urea linker in compound 2 with an acylsulfonamide linker kept a potent LDL-R up-regulatory activity, and subsequent optimization work gave compound 39 as a highly potent LDL-R up-regulator (39; EC25 = 0.047 mu M). Compound 39 showed no ACAT inhibitory activity even at 1 mu M. The sodium salts of compound 39 reduced plasma total and LDL cholesterol levels in a dose-dependent manner in an experimental animal model of hyperlipidemia. Moreover, we revealed in this study using RNA interference that autosomal recessive hypercholesterolemia (ARH), an adaptor protein of LDL-R, is essential for compound 39 up-regulation of LDL-R expression.

  DOI：

  10.1021/jm901909p
• 作为产物：
  描述：

  、 2,6-二异丙基苯基氨基磺酸 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 6.0h， 生成 2,6-diisopropylphenyl {[1-(2-methoxyphenyl)-4-(3-methoxyphenyl)piperidin-4-yl]carbonyl}sulfamate
  参考文献：
  名称：

  A Novel Class of Antihyperlipidemic Agents with Low Density Lipoprotein Receptor Up-Regulation via the Adaptor Protein Autosomal Recessive Hypercholesterolemia

  摘要：

  We have previously reported compound 2 as a inhibitor of acyl-coenzyme A:cholesterol O-acyltransferase (ACAT) and up-regulator of the low density lipoprotein receptor (LDL-R) expression. In this study we focused on compound 2, a unique LDL-R up-regulator, and describe the discovery of a novel class of up-regulators of LDL-R. Replacement the methylene urea linker in compound 2 with an acylsulfonamide linker kept a potent LDL-R up-regulatory activity, and subsequent optimization work gave compound 39 as a highly potent LDL-R up-regulator (39; EC25 = 0.047 mu M). Compound 39 showed no ACAT inhibitory activity even at 1 mu M. The sodium salts of compound 39 reduced plasma total and LDL cholesterol levels in a dose-dependent manner in an experimental animal model of hyperlipidemia. Moreover, we revealed in this study using RNA interference that autosomal recessive hypercholesterolemia (ARH), an adaptor protein of LDL-R, is essential for compound 39 up-regulation of LDL-R expression.

  DOI：

  10.1021/jm901909p

文献信息

• Novel Sulfonamide derivative
  申请人：Ban Hitoshi

  公开号：US20080096922A1

  公开（公告）日：2008-04-24

  A compound of the formula (1): wherein m, n and p is independently an integer of 0 to 4 with the proviso that 3≦m+n≦8; X is the formula: NR 4 , etc.; R 1 , R 3 and R 4 are a substituted or unsubstituted aryl group, etc.; R 2 is a hydrogen atom, etc.; a, b, c, d, e and f are a hydrogen atom or a substituted or unsubstituted alkyl group, etc.; Y is the formula: —SO 2 —, etc.; and Z is an oxygen atom, etc.; or a prodrug thereof or a pharmaceutically acceptable salt of the same has an activity of potentiating an expression of a low density lipoprotein receptor and thus is useful as an agent for treating hyperlipidemia or arteriosclerosis.

  公式（1）的化合物： 其中，m，n和p分别为0至4的整数，但须满足3≦m+n≦8；X为公式：NR4等；R1，R3和R4为取代或未取代的芳基基团等；R2为氢原子等；a，b，c，d，e和f为氢原子或取代或未取代的烷基基团等；Y为公式：—SO2—等；Z为氧原子等；或其前体药物或其药学上可接受的盐具有增强低密度脂蛋白受体表达的活性，因此可用作治疗高脂血症或动脉硬化的药物。
• NOVEL SULFONAMIDE DERIVATIVE
  申请人：Dainippon Sumitomo Pharma Co., Ltd.

  公开号：EP1736467A1

  公开（公告）日：2006-12-27

  A compound of the formula (1): wherein m, n and p is independently an integer of 0 to 4 with the proviso that 3 ≦ m + n ≦ 8; X is the formula: NR4, etc.; R1, R3 and R4 are a substituted or unsubstituted aryl group, etc.; R2 is a hydrogen atom, etc.; a, b, c, d, e and f are a hydrogen atom or a substituted or unsubstituted alkyl group, etc.; Y is the formula: -SO2-, etc.; and Z is an oxygen atom, etc.; or a prodrug thereof or a pharmaceutically acceptable salt of the same has an activity of potentiating an expression of a low density lipoprotein receptor and thus is useful as an agent for treating hyperlipidemia or arteriosclerosis.

  式 (1) 的化合物： 其中 m、n 和 p 独立地为 0 至 4 的整数，但 3 ≦ m + n ≦ 8；X 为式中的NR4等；R1、R3和R4是取代或未取代的芳基等；R2是氢原子等；a、b、c、d、e和f是氢原子或取代或未取代的烷基等；Y是式：-SO2-等：-SO2-等；Z是氧原子等； 或其原药或其药学上可接受的盐具有增强低密度脂蛋白受体表达的活性，因此可用作治疗高脂血症或动脉硬化的药物。
• EP1736467
  申请人：——

  公开号：——

  公开（公告）日：——
• A Novel Class of Antihyperlipidemic Agents with Low Density Lipoprotein Receptor Up-Regulation <i>via</i> the Adaptor Protein Autosomal Recessive Hypercholesterolemia
  作者：Shigehiro Asano、Hitoshi Ban、Norie Tsuboya、Shinsaku Uno、Kouichi Kino、Katsuhisa Ioriya、Masafumi Kitano、Yoshihide Ueno

  DOI：10.1021/jm901909p

  日期：2010.4.22

  We have previously reported compound 2 as a inhibitor of acyl-coenzyme A:cholesterol O-acyltransferase (ACAT) and up-regulator of the low density lipoprotein receptor (LDL-R) expression. In this study we focused on compound 2, a unique LDL-R up-regulator, and describe the discovery of a novel class of up-regulators of LDL-R. Replacement the methylene urea linker in compound 2 with an acylsulfonamide linker kept a potent LDL-R up-regulatory activity, and subsequent optimization work gave compound 39 as a highly potent LDL-R up-regulator (39; EC25 = 0.047 mu M). Compound 39 showed no ACAT inhibitory activity even at 1 mu M. The sodium salts of compound 39 reduced plasma total and LDL cholesterol levels in a dose-dependent manner in an experimental animal model of hyperlipidemia. Moreover, we revealed in this study using RNA interference that autosomal recessive hypercholesterolemia (ARH), an adaptor protein of LDL-R, is essential for compound 39 up-regulation of LDL-R expression.